Reference Message Network reported on April 7 according to a report on the website of Hong Kong's South China Morning Post on April 4. A new report shows that in the first quarter, the global expansion of China's biotechnology companies accelerated, with the number of overseas transactions increasing by 18% year-on-year, demonstrating strong momentum in the field of drug research.
According to a report released by China pharmaceutical and biotechnology consulting platform Drug Times on April 2, Chinese pharmaceutical manufacturers reached 33 deals with overseas healthcare companies in the first three months of this year, with a total transaction value of $36.2 billion.
The report shows that this figure is higher than the 28 overseas transactions in the first quarter last year. In 2024, Chinese companies had 98 transactions with a total value of $59.5 billion.
The largest deal in the first quarter totaled $13 billion. The parties involved were Suzhou-based Qidai Medicine, a Nasdaq-listed company Biohaven Pharmaceuticals, and AimedBio, based in Seoul. This transaction involves antibody-drug conjugates, a targeted therapy drug used for cancer treatment.
In a deal last quarter, Harmony Biosciences, a biotech company listed in Hong Kong, reached a global strategic cooperation agreement with AstraZeneca to jointly develop next-generation multi-specific antibody therapies for immune diseases, tumors, and other multiple diseases. According to Drug Times, this deal was worth $4.7 billion.
The steady growth of these deals (including licensing and joint ventures) reflects the expansion of China's pharmaceutical industry overseas.
It is pointed out that in recent years, as more Western major companies look to China for innovative drugs, China's biotechnology companies are playing an increasingly important role in the global pharmaceutical industry.
Despite the intensification of geopolitical tensions and the Trump administration imposing new tariffs on U.S. global trade partners, complicating the situation further, this trend continues.
Original article: https://www.toutiao.com/article/7490400800905134644/
Disclaimer: The article only represents the author's personal views. Please express your attitude by clicking the "Like/Dislike" buttons below.